Revised International Prognostic Scoring System (IPSS-R) for
Myelodysplastic Syndromes Risk Assessment Calculator


Developed by the International Working Group for the Prognosis of MDS (IWG-PM) under the aegis of the MDS Foundation, Inc.


When entering values into the calculator, note the units given in parentheses. Also note that the usual ranges, given for orientation, are in brackets. These are not normal ranges.

Variables (units) [usual range]

Hemoglobin (g/dL) [4-20]
A possible conversion for Hb values:
10 g/dL= 6.2 mmol/L, 8 g/dL= 5.0 mmol/L

Value

Absolute Neutrophil Count (x109/L) [0-15]
Platelets (x109/L) [0-2000]
Bone Marrow Blasts (percent) [0-30]

Cytogenetic Category

Very Good  Good  Intermediate  Poor  Very Poor 
IPSS-R SCORE
IPSS-R CATEGORY
Age-adjusted calculation of risk (IPSS-RA):
(only for survival estimation)


Age     Years
IPSS-R SCORE
IPSS-R CATEGORY(including age)
IPSS-R Cytogenetic risk groups*,**
Cytogenetic prognostic subgroups Cytogenetic abnormalities
Very good -Y, del(11q)
Good Normal, del(5q), del(12p), del(20q), double including del(5q)
Intermediate del(7q), +8, +19, i(17q), any other single or double independent clones
Poor -7, inv(3)/t(3q)/del(3q), double including -7/del(7q), Complex: 3 abnormalities
Very poor Complex: >3 abnormalities
IPSS-R Prognostic Score Values*
Prognostic variable 0 0.5 1 1.5 2 3 4
Cytogenetics Very Good Good Intermediate Poor Very Poor
BM Blast % <=2 >2-<5% 5-10% >10%
Hemoglobin =>10 8-<10 <8
Platelets =>100 50-<100 <50
ANC =>0.8 <0.8
IPSS-R Prognostic Risk Categories/Scores*
RISK CATEGORY RISK SCORE
Very Low <=1.5
Low >1.5 - 3
Intermediate >3 - 4.5
High >4.5 - 6
Very High >6
IPSS-R: Prognostic Risk Category Clinical Outcomes*
No. pts Very Low Low Intermediate High Very High
Patients (%) 7012 19% 38% 20% 13% 10%
Survival*** 8.8 5.3 3.0 1.6 0.8
AML/25%***,^ NR 10.8 3.2 1.4 0.7
***Medians, years ^Median time to 25% AML evolution
*Greenberg, Tuechler, Schanz et al, Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndrome, Blood 120: 2454, 2012.
**Schanz J et al, J Clin Oncology 2012; 30:820